Adhering to the principles of “investing early in small-scale, long-term, and hardcore technology”, our fund investment services focus on “5+X” key industries, which include artificial intelligence (AI), integrated circuits (IC), medicine & healthcare, new energy, new materials, and future industries. In addition to providing full-lifecycle “patient capital” services, the fund portfolio covers a wide range of vehicles, including scientist funds, Angel & VC funds, PE funds, strategic funds, mergers and acquisitions (M&A) funds, equity-debt hybrid funds, funds of funds (FoFs), and secondary funds. As of the end of June 2026, we have managed 64 funds, including 54 direct investment funds and 10 funds of funds, with total assets under management totaling RMB 58.9 billion. Our fund has invested in more than 4,200 projects, of which 603 are direct investments. Notable portfolio companies include SMIC (SH.688981), GigaDevice (SH.603986), NCS Testing Technology (SH.603444), BeiGene (SH.688235), UNISOC, Galbot, Qitan Tech, Xinzhida, and Weixin Perception. We have also supported the commercialization of research achievements from 49 academicians, including Wang Xiaodong and Shi Yigong.